Dr. Trinh received a $1.5M Department of Defense-Congressionally Directed Medical Research Programs (Health Disparity Research Award) Award for the project titled: “Increasing access to definitive treatment for prostate cancer by removing transportation barriers for underserved patients: A multilevel feasibility study.”
The proposed project uses a multi-pronged approach to better characterize and address the effects of greater travel burden on care access disparities. Geospatial methods will be used to generate higher resolution and more precise analyses of travel burden and to test a pilot rideshare intervention among Black men. In addition, qualitative research methods will be employed to identify facilitators and barriers of the rideshare intervention that can inform the implementation, sustainability and scaling up of successful intervention components.
Quoc-Dien Trinh, MD, MBA
Section Chief of Urology, Brigham and Women’s Faulkner Hospital
Co-Director, Dana-Farber/Brigham and Women’s Prostate Cancer Center
Associate Professor of Surgery, Harvard Medical School
Dr. Trinh is the section chief of urology at Brigham and Women’s Faulkner Hospital, an associate professor of surgery at Harvard Medical School and co-director of the Dana-Farber/Brigham and Women’s Prostate Cancer Center. Dr. Trinh is the 2021 recipient of the Brigham and Women’s Hospital Outstanding Citizenship Award and the 2022 American Urological Association Young Urologist of the Year. He is a core faculty and member of the Internal Advisory Board at the Center for Surgery and Public Health, a joint program of the Brigham, Harvard Medical School and the Harvard School of Public Health.
Dr. Trinh’s research focuses primarily on inequity and outcomes of cancer care delivery. He co-founded the Mass General Brigham Prostate Cancer Outreach Clinic, a United Against Racism initiative. He received his medical degree from the Université de Montréal in Canada, where he also completed his residency training in urology. He completed his fellowship in minimally invasive urologic oncology at the Vattikuti Urology Institute.